NCT02175433 (Clinical Trial/ AGS67E)

Study Title
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies (NCT02175433)

Trial Description
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of AGS67E both without and with myeloid growth factor (GF) in subjects with refractory or relapsed lymphoid malignancies. Immunogenicity and anticancer activity of AGS67E will also be assessed.

This trial is sponsored by Agensys, Inc. ®

Study Data

  • Condition:
    • Relapsed Lymphoid Malignancy
    • Refractory Lymphoid Malignancy
  • Interventions:
    • Drugs used in this trial
      • AGS67E
  • Phase: I
  • Enrollment: 85
  • Start: October 2014
  • Estimated Completion: June 2019
  • Last verified: May 2017
  • Last Updated: May 2017

Study Schematic

(Coming soon)

Click here to Return to Drug map

Last Editorial review: June 16, 2017
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.